Information and recommendations for doctors at hospitals/emergency departments

- Patients exposed only to epichlorohydrin vapor do not pose a significant risk of secondary contamination. Patients whose clothing or skin is contaminated with liquid epichlorohydrin can secondarily contaminate rescue and medical personnel by direct contact or through evaporation of epichlorohydrin.

- Epichlorohydrin can produce eye, skin, and respiratory tract irritation. Signs of pulmonary edema (shortness of breath, cyanosis, expectoration, cough) may evolve 12 hours or more after exposure. Skin reactions may be delayed and may heal very slowly.

- Inhalation and skin contact may result in systemic absorption resulting in headache, nausea, vomiting, abdominal pain, lung, liver, and kidney damage.

- There is no antidote to be administered to counteract the effects of epichlorohydrin. Treatment consists of supportive measures.

1. Substance information

   Epichlorohydrin (C₃H₅ClO), CAS 106-89-8
   Synonyms: 1-chloro-2,3-epoxypropane, 3-chloro-1,2-epoxypropane, 1-chloropropenoxide, 3-chloropropenoxide.
   Epichlorohydrin is a colorless and flammable liquid at room temperature (boiling point 116°C, 241°F, respectively) with an odor comparable to chloroform. However, dangerous exposures may occur at levels too low to smell. Epichlorohydrin vapor may form an explosive mixture with air and is heavier than air; exposure will be higher in enclosed, poorly ventilated, or low-lying areas. It is slightly soluble in water. Epichlorohydrin is used in the manufacture of epoxy and phenoxy resins, glycerol, surface active agents, pharmaceuticals, insecticides, coatings, adhesives, solvents, and other chemicals. It is used as a solvent in the rubber and paper industry.

2. Routes of exposure

   **Inhalation**
   Inhalation is a major route of epichlorohydrin exposure. Epichlorohydrin’s odor is not a reliable indicator of any level of exposure and provides insufficient warning of hazardous exposure.

   **Skin/eye contact**
   Epichlorohydrin vapor or liquids may be absorbed through the skin and eyes; however, direct contact with epichlorohydrin vapor or concentrated solutions may cause severe chemical burns.

   **Ingestion**
   Involuntary ingestion of epichlorohydrin is unlikely.

3. Acute health effects

   Exposure to epichlorohydrin concentrations of more than 10-20 ppm may produce irritation of the eyes, nose, and throat. Concentrations greater than 100 ppm may cause pulmonary edema up to 12 hours or more after exposure. Skin contact with epichlorohydrin vapor or liquid may cause irritation with redness of the skin, blistering, itching, and pain. Skin reactions may be delayed up to 12 hours or more after exposure and may heal very slowly.

   Epichlorohydrin is a potent skin sensitizer. High vapor concentrations or splashes of concentrated solutions can cause tearing and redness of the eye, and corneal injury.

Both inhalation and skin contact may lead to systemic absorption causing severe headache, nausea, vomiting, abdominal pain, and lung, liver and kidney injury.
Dose-effect relationships are as follows:

<table>
<thead>
<tr>
<th>Epichlorohydrin concentration</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 ppm</td>
<td>Odor detection</td>
</tr>
<tr>
<td>10-20 ppm</td>
<td>Mild transient mucous membrane irritation</td>
</tr>
<tr>
<td>40 ppm</td>
<td>Burning of eyes, nose, and throat, dyspnea, coughing; symptoms may persist for some days</td>
</tr>
<tr>
<td>&gt;100 ppm</td>
<td>Toxic pneumonitis and pulmonary edema; kidney lesions</td>
</tr>
<tr>
<td>Uptake of &gt;50 mg/kg body weight</td>
<td>Potentially lethal</td>
</tr>
</tbody>
</table>

Potential sequelae

Survivors of severe inhalation injury may suffer residual chronic lung disease or recurrent respiratory tract infections. Permanent liver or kidney damage may result from high systemic exposure.

Carcinogenicity

According to EC directive 1272/2008 epichlorohydrin is classified as follows:

Carc. 1B (known or presumed human carcinogen, classification is largely based on animal evidence)

4. Actions

Decontamination

Patients exposed only to epichlorohydrin vapor do not pose a significant risk of secondary contamination. Patients whose clothing or skin is contaminated with liquid epichlorohydrin can secondarily contaminate other people by direct contact or through evaporation of epichlorohydrin. Patients who are able and cooperative may assist with their own decontamination. If the exposure involved liquid epichlorohydrin and if clothing is contaminated, remove and double-bag the clothing.

Assure that skin and hair exposed to liquid containing epichlorohydrin have been flushed with plain water for at least 15 minutes. If not, continue flushing during other basic care. Protect eyes during flushing of skin and hair.

Assure that exposed or irritated eyes have been irrigated with plain water or saline for at least 15 minutes. If not, continue eye irrigation during other basic care.

Remove contact lenses if present and easily removable without additional trauma to the eye.

Initial treatment

Therapy will be empiric; there is no antidote to be administered to counteract the effects of epichlorohydrin.

All asymptomatic patients potentially exposed to an airborne epichlorohydrin concentration of 40 ppm or more should take 8 puffs of beclomethasone (800 µg beclomethasone dipropionate) from a metered dose inhaler, if not already done. Thereafter, 4 puffs every 2 hours for 24 hours.

The following measures are recommended if the airborne exposure concentration is 100 ppm or more and/or if patients have respiratory complaints or evidence of systemic toxic effects after inhalation of epichlorohydrin:

- Administration of oxygen
- Administration of 8 puffs of beclomethasone (800 µg beclomethasone dipropionate) from a metered dose inhaler.

Patients with severe clinical respiratory symptoms (e.g. bronchospasms, stridor) should be treated as follows:

a) Nebulized epinephrine (adrenaline): Mix 2 mg of epinephrine (2 ml) with 3 ml saline 0,9%. Administer via nebulizer mask.

b) Intravenous administration of 250 mg methylprednisolone (or an equivalent steroid dose) is recommended.
Patients with clinical signs of a toxic lung edema (e.g. foamy sputum, wet crackles) should be treated as follows:

a) Start CPAP-therapy (Continuous Positive Airway Pressure Ventilation).

b) Intravenous administration of 1000 mg methylprednisolone (or an equivalent steroid dose) is recommended.

Intubation of the trachea or an alternative airway management should be considered in cases of respiratory compromise. When the patient’s condition precludes this, consider cricothyrotomy if equipped and trained to do so.

Note: Efficacy of corticosteroid administration has not yet been proven in controlled clinical studies.

If epichlorohydrin was in contact with the skin, chemical burns may result; treat as thermal burns: adequate fluid resuscitation and administration of analgesics, maintenance of the body temperature, covering of the burn with a sterile pad or clean sheet. After eye exposure chemical burns may result; treat as thermal burns. Immediately consult an ophthalmologist.

Further evaluation and treatment

To the standard intake history, physical examination, and vital signs add pulse oximetry monitoring and a PA chest X-ray. Spirometry should be performed.

Routine laboratory studies should include a complete blood count, hepatic and renal function parameters, glucose and electrolyte determinations.

Consider hospitalization of patients who have evidence of systemic toxicity from any route of exposure.

Evidence of pulmonary edema - hilar enlargement, and ill-defined, central-patch infiltrates on chest radiography - is a late finding that may occur 12 hours or later after exposure. The chest X-ray is typically normal on first presentation to the emergency department even with severe exposures.

If oxygen saturation is less than 90 % or if it appears to drop, immediately check arterial blood gasses and repeat the chest X-ray. If blood gasses begin to show deterioration and/or if the chest X-ray begins to show pulmonary edema start oxygen supplementation.

In case of worsening clinical signs (especially tachypnea >30/min with a simultaneous decrease of the partial pressure of carbon dioxide) CPAP-therapy (Continuous Positive Airway Pressure Ventilation) should be started within the first 24 hours after exposure.

In case of a pulmonary edema fluid intake/output and electrolytes should be monitored closely. Avoid net positive fluid balance. Central line or Swan-Ganz catheterization might be considered, to optimize fluid management.

As long as signs of pulmonary edema are present, intravenous administration of methylprednisolone (or an equivalent steroid) should be continued in intervals of 8-12 hours.

Patients with persisting or therapy refractory bronchospasms should be treated as follows:

a) Nebulized epinephrine (adrenaline): Mix 2 mg of epinephrine (2 ml) with 3 ml saline 0,9%. Administer via nebulizer mask.

b) Consider aerolized ß2-selective adrenergic agonist, e.g. 4 puffs of terbutaline, or salbutamol, or fenoterol from a metered dose inhaler (1 puff usually contains 0.25 mg terbutaline sulfate, or 0.1 mg salbutamol, or 0.2 mg fenoterol, respectively); may be repeated once after 10 min.

c) If inhalation is not possible, terbutaline sulfate (0.25-0.5 mg) subcutaneously or salbutamol (0.2-0.4 mg over 15 min) intravenously.
Prophylactic antibiotics are not routinely recommended but may be used based on the results of sputum cultures. Pneumonia can complicate severe pulmonary edema. Consider hemodialysis in case of significant systemic absorption of epichlorohydrin with impairment of liver and/or kidney function.

Clinically asymptomatic patients exposed to a concentration of less than 40 ppm (depending on the period of time exposed) as well as patients who have a normal clinical examination and no signs or symptoms of toxicity may be discharged after an appropriate observation period in the following circumstances:

a) The evaluating physician is experienced in the evaluation of individuals with epichlorohydrin exposure.
b) Information and recommendations for patients with follow-up instructions are provided verbally and in writing. Patients are advised to seek medical care promptly if symptoms develop or recur.
c) The physician is comfortable that the patient understands the health effects of epichlorohydrin.
d) Site medical is notified, so that the patient may be contacted at regular intervals in the 24-hour period following release from the emergency department.
e) Heavy physical work should be precluded for up to 24 hours.
f) Exposure to cigarette smoke should be avoided for 72 hours; the smoke may worsen the condition of the lungs.

Patients who have eye exposures should be reexamined after 24 hours. For those patients with inhalation injury, post discharge spirometry should be repeated until values return to the patient’s baseline values.